Etsy Inc vs Natera Inc. Common Stock — how do they compare? Etsy Inc trades at $82.96 (market cap $7.28B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 7.8× Etsy Inc's market cap, and Etsy Inc is more actively traded (2,112,607 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Natera Inc. Common Stock for 0 Days on average.
| ETSY | NTRA | |
|---|---|---|
Market Cap | $7.28B | $57.03B |
Volume | 2,112,607 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $425.64 |
52-Week Low | $44.05 | $179.42 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $9.23B | $56.18B |
Signals from Pluang's Aura AI — not financial advice
ETSY is trading at $82.93, up 7.8% with strong momentum following three consecutive quarterly earnings beats. The stock shows bullish technical signals with positive moving averages and trades near analyst consensus targets. Recent news highlights AI integration initiatives and strategic partnerships, while financials show solid revenue growth but declining net margins from 11.19% in 2023 to 5.65% in 2025.
Outlook remains cautiously optimistic with 53% analyst buy ratings and $85.94 consensus target, though high P/B ratio and negative equity raise valuation concerns. Key risks include margin compression and competitive e-commerce pressures, while institutional accumulation and AI-driven personalization initiatives provide growth catalysts.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →